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Abstract 
Background 
Exposure to particulate air pollution increases respiratory and cardiov scular morbidity and 
mortality, especially in elderly, possibly through inflammation and vascular dysfunction. 
Methods 
We examined potential beneficial effects of indoor air filtration in the homes of elderly, 
including people taking vasoactive drugs. 
Forty-eight nonsmoking subjects (51 to 81 years) in 27 homes were included in this 
randomized, double-blind, crossover intervention study with consecutive two-week periods 
with or without the inclusion of a high-efficiency particle air filter in re-circulating custom 
built units in their living room and bedroom. We measured blood pressure, microvascular and 
lung function and collected blood samples for hematological, inflammation monocyte surface 
and lung cell damage markers before and at day 2, 7 and 14 during each exposure scenario. 
Results 
The particle filters reduced the median concentration of PM2.5 from approximately 8 to 4 
µg/m3 and the particle number concentration from 7669 to 5352 particles/cm3. No statistically 
significant effects of filtration as category were observed on microvascular and lung function 
or the biomarkers of systemic inflammation among all subjects, or in the subgroups taking (n 
= 11) or not taking vasoactive drugs (n = 37). However, the filtration efficacy was variable 
and microvascular function was within 2 days significantly increased with the actual PM2.5 
decrease in the bedroom, especially among 25 subjects not taking any drugs. 
Conclusion 
Substantial exposure contrasts in the bedroom and no confounding by drugs appear required 
for improved microvascular function by air filtration, whereas no other beneficial effect was 
found in this elderly population. 
Keywords 
Endothelial function, Indoor air pollution, Intervention, Inflammation, Lung function, 
Particles 
Background 
Exposure to particulate air pollution increases mortality and morbidity related to respiratory 
and cardiovascular diseases especially among susceptible individuals such as the elderly and 
people with pre-existing lung- and heart disease [1]. The underlying biological mechanisms 
are considered to include oxidative stress and inflammation. For cardiov scular disease these 
mechanisms include the pulmonary release of inflammatory and vasoactive molecules into 
the circulation, altered cardiac autonomic function, altered balance between coagulation and 
fibrinolysis, endothelial and microvascular dysfunction, atherosclerosis progression and 
plaque instability [2]. Ultrafine particles (diameter less than 100 nm), especially from 
combustion processes in vehicles, are thought to have particularly detrimental effects due to 
high alveolar deposition, poor clearance, large reactive surface area with attached metals and 
polycyclic aromatic hydrocarbons (PAH) on their carbonaceous core, and potential for 
translocation to the systemic circulation [3]. 
Health effects of exposure to air pollution is mainly related to outdoor levels, monitored or 
modeled in areas around residences. However, most people, especially those from the 
susceptible groups spend over 80–90% of their day indoors [4,5]. Although traffic-related 
particles are transported into the indoor environment by ventilation and infiltration [6], this is 
highly variable and a large proportion of indoor particles comes from a variety of indoor 
sources (frying, candles burning, heating devices, environmental tobacco smoke, office 
equipment, chemical reactions, biological sources and human activity), which may account 
for the majority of total personal exposure [7-9]. Biomarkers related to risk of cardiovascular 
and other diseases appear more strongly associated with personal exposur  to particles than 
with ambient particulate air pollution levels [10,11]. Yet, little is known about the adverse 
effects of exposure to indoor-generated particles, except for the indoor allergens and aerosols 
on individuals with respiratory allergies or asthma [12]. Substantial reductions in exposure to 
particles can be achieved by portable air filtration units in the indoor environment allowing 
assessment of causality, understanding mechanistic endpoints, identification of relevant 
sources and development of large scale long-term interventions in relevant risk groups. 
In a study of elderly (60–75 years) people, an 8% improvement in microvascular function 
measured by EndoPAT2000 (MVF) was detected following 48 hours of air filtration in their 
homes [13]. Similarly, significant improvement of MVF and a reduction in biomarkers of 
inflammation were found in 45 subjects aged 20 to 63 years after one week indoor air 
filtration in homes in wood smoke-impacted areas [14]. A recent review concluded that 
residential air filtration can improve outcomes in the treatment of allergic respiratory diseases 
[12]. Lung function was improved in young adults after filtration of tobacco smoke-polluted 
indoor air in the home, whereas the MVF was unchanged [15]. 
The objective of this study was test the hypothesis that prolonged i tervention with indoor air 
filtration of PM in the home improves MVF and lung function in an elderly representative 
non-smoking population, including people taking vasoactive and other drugs. In two 
consecutive two-week periods re-circulating custom built particle f ltration units with the 
inclusion of a high-efficiency particle air (HEPA) alternati g with sham filters were installed 
in the living room and bedroom. Secondary endpoints assessed included blood pressure, 
markers of systemic inflammation in terms of C-reactive protein and white blood cell counts 
previously shown to be affected by indoor air filtration [13,14], plasma levels of Clara cell 
pneumoproteins (CC16) and surfactant protein D (SPD) as sensitive biomarkers of epithelial 
damage in the lower airways [16,17], and the expression of surface adhesion molecules in 
terms of CD11b, CD31, CD49 and CD62L on circulating monocytes by flow cytometry, 
because monocyte activation with adherence to the endothelium is an important event in the 
atherosclerotic process [18]. 
Materials and methods 
The study protocol was approved by the regional ethics committee for human studies in 
Copenhagen (H-4-2010-102). All participants gave written informed consent prior to 
enrolment in the study. 
Study subjects and design 
We recruited 51 (22 couples and 7 singles) non-smoking volunteers aged over 51 years and 
living in Greater Copenhagen in non-smoking apartments within 350 m (min 25 m, max 1000 
m) from major roads (>10,000 vehicles per day) using radio spots as well as notices in local 
newspapers, activity centers and supermarkets. One couple and a single person later resigned, 
leaving 21 couples and 6 singles (22 men and 26 women) aged 51 to 81 years as the study 
population (Table 1). Eleven participants were taking vasoactive drugs (angiotensin-
converting enzyme (ACE) inhibitors, calcium channel blockers, or β-adrenoreceptor 
blockers), 11 participants were taking statins and 12 participants were taking cyclooxygenase 
inhibitors (acetyl salicylic acid, ibuprofen or paracetamol). Two participants had diagnosed 
asthma and one participant had diabetes treated with metformin. According to diaries the 
participants spend in median (5th, 95th percentiles) 83% (67%, 92%) of their time at home. 
This was similar for the periods with and without filtration 83% (63%, 92%) and 83% (67%, 
92%), respectively. 
Table 1 Characteristics of the study participants 
Characteristics of participants Men Women Total 
Gender 22 26 48 
Age (years) 67.7 ± 6.6 66.4 ± 6.6 67 ± 6.5 
Height (cm) 180 ± 6.2 167 ± 5.0 173 ± 8.7 
Weight (kg) 83 ± 12.2 69 ± 10.9 75 ± 13.4 
Body mass index (kg/m2) 25.5 ± 3.1 24.6 ± 3.1 25 ± 3.1 
Diastolic blood pressure (mmHg) 78 ± 7.7 77 ± 6.5 77 ± 7 
Systolic blood pressure (mmHg) 127 ± 15.1 121 ± 11.8 124 ± 13.6 
Total cholesterol (mmol/L) 3.7 ± 0.8 4.3 ± 1.1 4 ± 1.0 
LDL cholesterol (mmol/L) 2 ± 0.5 2.2 ± 0.7 2.1 ± 0.6 
HDL cholesterol (mmol/L) 1.1 ± 0.3 1.5 ± 0.4 1.3 ± 0.4 
Triglycerides (mmol/L) 1 ± 0.5 0.8 ± 0.3 0.9 ± 0.4 
Subjects taking vasoactive medication 9 2 11 
Subjects taking statins 5 6 11 
Subjects taking cyclooxygenase inhibitors 5 7 12 
Subjects not taking any drugs 12 11 23 
Values are number or mean ± SD. LDL, Low-density lipoprotein; HDL, High-density lipoprotein. 
The project was designed as a double-blind cross-over intervention with randomized order of 
exposure to re-circulated particle-filtered or sham-filtered in oor air in the home of the 
participants. Each exposure lasted for a 14-day period and the subject  served as their own 
controls, excluding confounding by characteristics that are stable within an individual over 
time, but vary between participants. All measurements were completed within a 7-month 
period starting November 2010, which corresponds to the same seasonal period as in our 
previous similar study carried out 4 years earlier [13]. 
Indoor air was re-circulated within each exposure period using custom built units with or 
without the inclusion of a HEPA filter class H11 (EN1822) placed in the living room and 
bedroom of each home. In the period with sham filtration, we used a dummy filter that 
conferred the same pressure drop and noise level. The participants as well as the researcher 
measuring health outcomes were blinded to the exposure scenario. Information about health, 
lifestyle housing and indoor climate were registered using self-administered questionnaires. 
We measured MVF and lung function and all biomarkers in the morning at baseline (day 0) 
before start of air recirculation, and day 2, 7 and 14 of each exposure scenario. The same 
experienced researcher determined MVF and lung function and collected blood samples in all 
the participants’ homes. 
Exposure assessment 
Particle number concentrations (PNC) were continuously monitored with a t me resolution of 
16 seconds with Philips NanoTracer1000 (Philips Aerasense, Eindhoven, Netherlands). This 
instrument detects PNC and average diameter of particles between 10 and 300 nm according 
to the manufacturer. In each home one instrument was placed in the living room for 24 hours 
at baseline, before turning on the air re-circulating units and in the end of each exposure 
scenario. 
The level of PM2.5 (mass of particulate matter with aerodynamic diameter less than 2.5 µm) 
was measured in the bedroom and living room of each home. BGI 400 pumps collected air 
samples continuously at a constant flow rate (4 L min-1) through cyclone sampling heads GK 
2.05-KTL (BGI Incorporated, USA). Suspended matter in the PM2.5 range was separated on 
Zefluor W/PAD 37 mm filter membranes (Sigma-Aldrich) replaced weekly. The PM2.5 mass 
was determined gravimetrically and the mass data have recently been reported elsewhere 
[19]. The material on the filters from the second week of each xposure scenario was also 
analyzed for black carbon (BC) at 880 nm and ultraviolet-absorbing particul te matter 
(UVPM) at 370 nm thought to be a measure indicative of aromatic organic compounds by 
Dual-Wavelength Optical Transmissometer using a Magee Aethalometer AE22 (© Magee 
Scientific Corp., Berkeley, CA) and PAH content using gas chromatography–mass 
spectrometry (GC-MS) [20]. PAH were sampled on filter only, therefore the levels of more 
volatile PAH (2–4 rings) may have been underestimated due to losses during sampling. 
Measurement of microvascular and lung function 
MVF was measured non-invasively by peripheral arterial tonometry using the portable 
EndoPAT2000 (Itamar Medical Ltd, Cesaria, Israel), as previously describ d [21]. The 
method quantifies vascular function changes in the digital pulse waveform (PAT signal), 
measured with a pair of bio-sensors placed on the index finger of each hand. With 
participants seated in a quiet room a blood pressure cuff was placed above the elbow on one 
arm, while the contra-lateral arm served as a control arm. Resting blood pressure was 
measured using a WelchAllyn DuraShock DS54 manometer (Welch Allyn GmbH & Co. KG, 
Deutschland) before each MVF measurement. The EndoPAT2000 measurement consisted of 
a five minutes baseline, five minutes ischemic stimulus induced by supra-systolic cuff 
occlusion of flow through the brachial artery on the test arm and reactiv  hyperemia recorded 
for further five minutes after cuff deflation. The response to reactive hyperemia was 
calculated automatically through a computer algorithm as the ratio of the post and pre 
occlusion values normalized to measurements from the control arm. 
Spirometry was performed in accordance with the American Thoracic Society/European 
Respiratory Society standard guidelines [22] using the NDD EasyOne Plus spirometer (ndd 
Medical Technologies; Zurich Switzerland). Forced expiratory volume in first second (FEV1) 
and forced vital capacity (FVC) were collected after MVF measurements. The data were 
digitally stored and the largest FVC and FEV1 from at least three acceptable maneuvers were 
used; the ratio of FEV1 to FVC was calculated. 
Biomarkers in blood 
Blood samples were collected on the day of home visits. Peripheral venous blood samples 
were collected in CPTTM tubes with sodium heparin (BD Vacutainer® CPT™, Becton 
Dickinson A/S, Brøndby, Denmark) for peripheral blood mononuclear cells (PBMC) 
isolation and in EDTA tubes for hematological analyses. Within four hours we measured 
hemoglobin and leukocyte counts and their differential profile: lymphocytes, monocytes, 
granulocytes with a multiplatform analyzer (Chempaq XBC, by Denmark). We separated 
PBMC for storage at −80°C in freezing media consisting of 50% fetal bovine serum (FBS, 
GibcoRBL), 40% culture medium (RPMI 1640, GibcoRBL) and 10% dimetyl sulfoxide for 
flow cytometry analyses. 
Plasma C-reactive protein (CRP), total cholesterol, high-density lipoprotein, low-density 
lipoprotein and triglycerides were analyzed at the Department of Clinical Biochemistry, 
Copenhagen University Hospital. 
The concentrations of CC16 and SPD in plasma were analyzed by ELISA (Human Clara Cell 
Protein ELISA kit from BioVendor Laboratory Medicine, Inc., Brno, Czech Republic) at the 
Department of Occupational and Environmental Medicine, Sahlgrenska University Hospital 
and Sahlgrenska Academy, University of Gothenburg. 
Direct immunofluorescence of PBMCs was performed on a BD Accuri™ C6 flow cytometer 
with BD Accuri CFlow®Plus software (BD Bioscience, Brøndby, Denmark) with all 7 
samples from each participant analyzed in the same batch. Specific surface staining of the 
activation status of monocytes was performed with fluorescein isothiocyanate (FITC)-
conjugated anti-CD49d (ITGA4), + Allophycocyanin (APC)-conjugated anti-CD11b 
(Mac1α) and FITC-conjugated anti-CD31 (PECAM-1) + Phycoerythrin (PE)-conjugated anti-
CD62L (L-selectin) mouse monoclonal antibodies (BD Bioscience, Brøndby, Denmark). BD 
Compbeads stained with individual fluorescent probes were used to set up compensation; 
unstained cells were used to determine the baseline fluorescence of the monocyte population 
and cells stained with isotype-matched FITC, PE and APC-conjugated human 
immunoglobulin G were used as negative controls. 
The samples were quickly thawed at 37°C for 1–2 min, 10 ml warm cRPMI was added and 
the tubes were centrifuged at 400 g for 7 minutes. Cells were then resuspended in 1 ml warm 
cRPMI, counted with a hemocytometer and scored for viability by trypan blue exclusion. 
PBMCs were placed in round-bottom 96-well plates (ca. 105 per well), stained for 30 min at 
4°C, washed twice with stain buffer with centrifugation at 250 g for 5 min, resuspended in 
100 µl stain buffer and analyzed immediately. Monocytes were selectively gated based on 
their characteristic forward scatter and side scatter properties. The expression of CD11b, 
CD31, CD62L and CD49d on monocytes was quantified as percentage of positive cells from 
each sample. 
Statistical analysis 
We used linear mixed models (xtmixed procedure in STATA 12.0) to estimate the effect of 
air filtration presented as a percent change with 95% confidence intervals on log-transformed 
outcomes, accounting for correlation between repeated measurements within individuals and 
for correlation between individuals (couples) living at same residence. Separate models of the 
effect of filtration as categorical variable were fitted for each of the three time points during 
the two weeks with or without filtration and overall for each outcome, adjusted for baseline 
level, BMI, age, and gender because participants with incomplete data were included. The 
potential modifying effect of vasoactive medication, statins and cyclooxygenase inhibitors on 
the effect of filtration was tested by inclusion of an interaction erm in the model and tested 
by Wald test. In addition, we modeled each outcome on the actual decrease in PM2.5 
concentration measured in the bedroom and living room during the filtration period for each 
of the three time points and overall, adjusted for baseline level, BMI, age, and gender. All 
models were also run without inclusion of baseline values as sensitivity analyses. The study 
was powered to detect an 8% change in microvascular function among 37 participants with 
type I and II error levels of 5% and 10%, respectively. 
Results 
A total of 48 people from 27 dwellings participated in the study. Forty-five participants had 
seven home visits and three participants only had five home visits, resulting in a total of 187 
home visits with 330 sets of measurements. One baseline MVF test and 14 spirometer tests 
were not recorded due to instrument failure. 
The air filtration intervention in the 27 study homes resulted in a reduction of 30% in PNC in 
the living room and close to 50% of PM2.5 in both living room and bedroom (Table 2). The 
efficacy of the filtration was variable with changes in PM2.5 ranging from a reduction of 24 
µg/m3 to an increase of 7 µg/m3 in the bedroom and from a 20 µg/m3 decrease to a 4 µg/m3 
increase in the living room, respectively. The reductions in PAH, BC and UVPM were 
similar to the PM2.5 reduction. The outcomes at baseline and day 2, 7 and 14 of the repeated 
measurements within each exposure scenario are presented in Table 3. The baselin  MVF and 
FEV1/FVC blood were in keeping with a relatively healthy elderly population. There was no 
significant effect of the intervention as categorical variable on the MVF or lung function on 
any day of the days studied during the two-week period. 
Table 2 Particle exposure in the homes of the participants during sham and active indoor air filtration  
Filtration  Living room  Bedroom 
Sham Active Sham Active 
Particle number count (#/cm3) 7669 (3435–45866) 5352 (1241–56654) ND ND 
PM 2.5 total mass
a (µg/m3) 8.0 (3.4-20.7) 4.3 (0.2-12.2) 7.6 (1.4-19.1) 3.7 (0–14) 
PM 2.5 black carbon (BC) (ng/m
3) ND ND 480 (199–1328) 219 (19.6- 545) 
PM 2.5 UV absorbing PM UVPM (ng/m
3) ND ND 361 (191–792) 201 (43.5- 454) 
PAHb (ng/m3) 0.48 (0.06-2.4) 0.25 (0.02-2)   
Values are median (5th, 95th percentile). ND: not determined. 
a PM 2.5 total mass data have recently been reported elsewher  [19]. 
b sum of 13 different polycyclic aromatic hydrocarbons (PAH): phenanthrene, anthracene, fluoranthene, pyrene, benzo(a)anthracene, chrysene, benzo(b)fluoranthene, 
benzo(k)fluoranthene, benzo(a)pyrene, perylene, indeno(1,2,3-c,d)pyrene, dibenzo(a,h)anthracene, benzo(g,h,i)perylene. 
Table 3 Median (5th, 95th percentile) of the outcomes at baseline as well as according to each exposure scenario 
Biomarkers Baseline Sham filtration  Active filtration  
 Day 0 Day 2 Day 7 Day 14 Day 2 Day 7 Day 14 
MVF 1.69 (1.07, 2.87) 1.74 (1.22, 2.60) 1.80 (1.30, 2.96) 1.72 (1.38, 2.56) 1.73 (1.20, 2.78) 1.69 (1.27, 2.63) 1.73 (1.32, 2.84) 
Diastolic pressure, (mmHg) 80 (70, 90) 78 (60, 90) 80 (70, 90) 80 (60, 90) 80 (65, 90) 80 (60, 95) 77.5 (60, 90) 
Systolic pressure, (mmHg) 130 (100, 150) 120 (90, 15 ) 120 (105, 140) 120 (100, 150) 125 (95, 140) 120 (95, 150) 120 (100, 140) 
C-reactive protein (mg/L) 0.8 (0.2, 4.9) 0.9 (0.2, 3.6) 0.9 (0.2, 5.5) 0.9 (0.2, 4.5) 0.9 (0.1, 4.7) 1.0 (0.2, 5.1) 0.9 (0.2, 4.3) 
Hemoglobin (mmol/L) 9.6 (7.8, 10.7) 9.3 (8.0, 11.2) 9.0 (7.9, 11.4) 9.1 (7.9, 10.8) 9.2 (8.0, 10.5) 9.1 (8.0, 10.3) 9.2 (7.6, 11.7) 
Leukocytes (×109celle/L) 5.6 (4.1, 8.3) 5.9 (4.1, 7.6) 5.6 (3.8, 8.3) 5.1 (3.8, 8.8) 5.7 (4.0, 8.1) 5.5 (3.9, 8.9) 5.8 (3. , 7.8) 
Lymphocytes (×109cells/L) 1.9 (0.9, 3.5) 1.8 (0.9, 3.4) 2.0 (0.8, 3.5) 1.9 (1.0, 3.2) 2.1 (1.1, 3.0) 2.0 (1, 3.6) 1.9 (0.9, 3.0) 
Monocytes (×109cells/L) 0.6 (0.4, 0.9) 0.6 (0.4, 0.8) 0.6 (0.3, 0.9) 0.6 (0.4, 0.9) 0.6 (0.4, 0.9) 0.6 (0.4, 0.9) 0.6 (0.4, 0.9) 
Granulocytes (×109cells/L) 3.0 (2.0, 4.8) 3.2 (1.9, 4.9) 2.6 (1.8, 5.3) 2.9 (1.9, 5.5) 2.9 (1.7, 4.9) 2.7 (1.8, 5.4) 3.0 (1.7, 5.4) 
CD31 93.8 (84.6, 97.9) 92.9 (85.2, 98.0) 93.6 (85.2, 98.1) 91.5 (81.1, 96.9) 94.3 (84.0, 97.9) 93.1 (79.4, 97.9) 92.0 (78.1, 97.9) 
CD62L 60.0 (40.7, 86.0) 63.6 (42.7, 79.0) 62.9 (44.1, 76.8) 61.9 (39.3, 77.9) 62.4 (45.7, 75.3) 60.7 (43.5, 80.7) 62.4 (44.1, 81.4) 
CD11b 33.7 (4.9, 63.7) 39.6 (4.0, 69.9) 41.8 (6.2, 76.2) 37.8 (12.6, 65.8) 41.5 (8.3,70.0) 35.8 (10.0, 62.6) 37.6 (6.7, 73.5) 
CD49d 60.5 (30.0, 95.5) 72.7 (32.4, 94.8) 76.7 (33.8, 94.3) 74.9 (32.6, 95.1) 72.4 (45.3, 96.5) 73.3 (0.7, 96.5) 71.5 (39.2, 95) 
FEV1/FVC 0.72 (0.42, 1.20) 0.66 (0.47, 1.17) 0.74 (0.38, 1.20) 0.72 (0.45, 1.37) 0.74 (0.38, 1.20) 0.73 (0.46, 1.43) 0.73 (0.43, 1.18) 
CC16 (ng/ml) 4.2 (2.0, 8.8) 3.5 (2.0, 9.4) 3.6 (2.0, 9.3) 4.0 (2.0, 8.36) 3.6 (2.0, 8.6) 4.3 (2.0, 10.7) 3.9 (2.0, 10.2) 
SPD (ng/mL) 100.6 (42.0, 285) 100.6 (46.1, 302.8) 99.0 (51.2, 279.2) 97.6 (46.2, 283.8) 103.1 (42.6, 30 .1) 94.3 (43.3, 294.2) 98.7 (50.9, 338.7) 
MVF, microvascular function; CD, cluster of differentiation; FEV1, Forced expiratory volume 1 s (L); FVC, Forced vital capacity (L); CC16, Clara cell pneumoprotein 16; SPD, surface protein 
D.
The estimated overall differences between active and sham filtration were −1.4% and 0.8% 
for all days analyzed together for MVF and lung function, respectively (Table 4). On the 
individual measurement day 2, 7 and 14 of the study periods there were only small changes in 
both upwards and downward directions. Similarly there was no significa t effect of the 
intervention on the biomarkers except for a 4% decrease in CD62L expression on day 2 of 
active filtration in contrast to a non-significant increase of 6% in this marker on day 14. For 
most of the remaining biomarkers the estimated changes were within a few percent with 
rather narrow 95% CI except for CRP, and CD11b expression that showed mor  variation, 
however, without sign of a filtration-related pattern. Results in terms of effect of air filtration 
as categorical variable were not sensitive to adjustment for the baseline measurement, 
window opening, age, gender, or BMI with very similar effect estimates with or without 
adjustment (data not shown). 
Table 4 Percent changes (95% confidence interval) in outcome levels, according to exposure scenario comparing active to sham 
filtration estimated by mixed-effects models adjusted for BMI, age and gender 
Biomarkers Day 2 Day 7 Day 14 Overall (all days) 
MVF −1.4 (−9.1, 7.0) −5.2 (−12.5, 2.7) 2.8 (−5.6, 12.0) −1.4 (−5.8, 3.2) 
C-reactive protein 3.7 (−15.3, 26.9) −11.3 (−29.1,10.9) −3.6 (−24.9, 23.8) −4.5 (−15.5, 7.9) 
Hemoglobin −2.2 (−5.7, 1.4) −2.1 (−5.5, 1.3) −5.2 (−14.7, 5.3) −3.2 (−6.9, 0.7) 
Leukocytes −0.7 (−6.6, 5.6) −0.7 (−6.0, 5.0) 2.4 (−3.1, 8.3) 0.2 (−3.1, 3.6) 
Lymphocytes 3 (−3.7, 10.1) −0.6 (−7.5, 6.9) 3.4 (−5.1, 12.6) 1.7 (−2.4, 6.1) 
Monocytes −0.4 (−5.8, 6.1) −1.5 (−7.1, 4.3) 2.2 (−4.5, 9.4) 0.05 (−3.3, 3.5) 
Granulocytes −3.8 (−12.4, 5.6) 0.5 (−7.9, 9.7) 2.4 (−5.9, 11.6) −0.4 (−5.3, 4.7) 
CD31 −0.01 (−1.4, 1.4) −3.7 (−9.1, 2.1) 1.3 (−1.7, 4.4) −0.8 (−3.1, 1.5) 
CD62L −4.4*(−8.4, -0.2) −2.9 (−10.7, 5.6) 6.1 (−0.3, 12.9) −0.4 (−4.2, 3.7) 
CD11b 10.4 (−9.1, 34.3) −6.2 (−19.3, 9.0) −11.4 (−26.2, 6.4) −3.1 (−12.5, 7.4) 
CD49d 1.3 (−11.8, 16.4) −2.2 (−9.1, 5.3) −2.9 (−11.5, 6.5) −1.3 (−6.9, 4.7) 
FEV1/FVC 0.16 (−12.1, 14.1) 5.1 (−5.4, 16.8) −2.2 (−9.2, 5.4) 0.8 (−5.1, 7.1) 
CC16 −0.4 (−10.1, 10.3) −1 (−13.4, 13.3) 0.2 (−8.8, 10.2) −0.3 (−6.4, 6.1) 
SPD −0.2 (−7.3, 7.4) −2 (−8.1, 4.5) 5.1 (−1.7, 12.5) 0.9(−2.8, 4.7) 
MVF, microvascular function; CD, cluster of differentiation; FEV1, Forced expiratory volume 1 s (L); FVC, Forced vital capacity (L); CC16, Clara cell pneumoprotein 16; 
SPD, surface protein D. *p<0.05.
There was no sign of modification of the effect assessed as active versus sham filtration by 
intake of drugs on outcome variables or different responses in any subgroups (Table 5; data 
only shown for MVF). 
Table 5 Percent change (95% confidence interval) in microvascular function comparing 
active to sham filtration and corresponding to a 10 µg/m3decrease in PM2.5 in the 
bedroom, estimated by mixed-effects models adjusted for BMI, age and gender and 
stratified according to medication 
Medication Active versus sham filter Per 10 µg/m3 decrease in PM2.5  
in the bedroom 
Medication No medication Medication No medication 
Vasoactive (n = 11) −3.7 (−13.4, 7.0) −0.7 (−5.6, 4.5) −2.3 (−14.7, 11.8) 7.7 (2.3, 13.3)* 
Statins (n = 11) −0.8 (−8.8, 8.0) −1.6 (−6.8, 3.9) 1.5 (−9.0, 13.3) 7.7 (1.1, 14.6)* 
Cyclooxygenase inhibitors (n = 12) −5.0 (−11.0, 1.5) −0.1 (−5.7, 5.8) 4.2 (−2.1, 10.9) 7.8 (0.5, 15.5)* 
Any drug (n = 23) −3.17 (−8.8, 2.8) 0.37 (−6.4, 7.7) 3.3 (−3.9, 11.9) 8.4 (2.0, 15.1)* 
*P < 0.05. 
The variable efficacy in the filtration led to a post-hoc analysis of the effect of the actually 
achieved decrease in PM2.5 on the outcomes. This indicated that MVF was positively and 
significantly associated with the decrease in PM2.5 in the bedroom overall and on day 2 of the 
filtration period as well as in subjects not taking drugs, whereas there was no sign of such 
association among subjects taking vasoactive drugs (Figure 1 and Table 4). The decrease in 
PM2.5 in the living room showed a similar but less strong and not significa t association with 
MVF (Figure 1). None of the other outcome variables showed significat associations with 
decreases in PM2.5, except CD62L, which showed a 9.4% (95% confidence interval: 1.5% to 
18%) increase per 10 µg/m3 decrease in the living room (other data not shown). 
Figure 1 Percent change with 95% confidence interval in microvascular function 
corresponding to a 10 µg/m3decrease in PM2.5 in the bedroom and living room after 2, 7 
and 14 days of active filtration and all 3 days combined, estimated by mixed-effects 
models adjusted for baseline level, BMI, age and gender. 
Discussion 
We found unaltered MVF, lung function and biomarkers comparing active and sham re-
circulating indoor filtration for two weeks in the homes of non-smoking elderly, including 
some with well-controlled vascular disease. With three measurements during each exposure 
scenario we are unlikely to have missed temporal changes. The indoor air filt ation reduced 
the median PM2.5 concentrations from approximately 8 to 4 µg/m
3, with similar decreases in 
BC and PAH that were already low, whereas the median PNC decreased from 7669 to 5352 
particles/cm3. The filtration efficacy was variable with changes in PM2.5 ranging from a 7 
µg/m3 increase to a 24 µg/m3 decrease. This led to a post-hoc analyses showing significantly 
improved MVF related to the decrease in the bedroom especially after two days filtration of 
the study period and in people not taking drugs, whereas the living room levels showed less 
strong and non-significant associations. The participants spent 83% of thetime at home, 
which could not be restricted to the living room with air re-circulating unit during the 
daytime of the four weeks study. In comparison, our previous study with 48 hours air 
filtration reduced the PM2.5 and PNC from 13 to 5 µg/m
3 and 10,000 to 3,200 particles/cm3, 
respectively. This was associated with improved MVF by 8% (95% CI: 0.4%, 16%) after two 
days in non-smoking elderly subjects, who did not take vasoactive drugs and stayed 92-94% 
of the time at home in only the two rooms with air filtration units [13]. Accordingly, our two 
air filtration studies on MVF among elderly appear compatible and even the 95% CI of the 
effects on MVF overlap related to active versus sham filtration. The difference in baseline 
levels of PM2.5 and PNC is partly consistent with decreasing outdoor PNC monitored at a 
busy urban street in Copenhagen in the period including our two filtration studies performed 
in 2006 (22,809 particles/cm3) and 2010/2011 (14,000 particles/cm3), respectively [23,24]. In 
the same period there has been increasing health consciousness becau e indoor smoking in 
public places has been banned (2007) and indoor sources of particles such as frying and 
candle use have been in public debate. Our realistic and relatively long air filtration 
intervention suggests that beneficial effects of further improvement of indoor air particle 
levels might be difficult to detect unless substantial exposure contrasts with possible 
emphasis on the bedroom are achieved. Nevertheless there was unaltered MVF among 37 
young adults after filtration of indoor air with electrostatic filters in 20 homes polluted by 
tobacco smoke with a 37 µg/m3 reduction in PM2.5 [15]. In contrast, significant improvement 
in MVF was found in 45 healthy subjects aged 20 to 63 years, after one week HEPA filtration 
of indoor air in the main activity room and the bedroom for seven days in non-smoking 
homes in wood smoke-impacted areas [14]. The filtration reduced PM2.5 from 11.2 to 4.6 
µg/m3. Wood smoke is not likely to be particularly toxic because short-term exposures to 
200–400 µg/m3 showed no effect on the MVF [25,26], whereas similar levels of diesel 
emissions have consistently shown impaired vasomotor responses [27,28]. 
Significant decreases in blood pressure and heart rate among young ad lts have been 
associated with 48-hours lasting reduction of indoor PM2.5 exposure after filtration reducing 
levels from around 24 to 18 µg m3 although not in a random study design [29]. Similarly, 
increased arterial blood pressure was associated with high ambient particle level and the heart 
rate variability and signs of ischemia were reduced by wearing a highly efficient facemask 
among patients with coronary heart disease [30]. However, we did not find effect of air 
filtration on blood pressure, which is consistent with our previous air filtration study and 
similar studies in wood smoke-impacted community and among First Nation Community 
[13-15]. 
High leukocyte counts and their subtypes can be biomarkers of vascular inflammation and 
predictor of coronary heart disease risk [31]. Short-term increases in ambient PM levels of 
have been associated with elevated numbers of circulating leukocytes in the general 
population and patients with chronic pulmonary diseases [32,33]. In contrast, no effects on 
leukocytes or granulocytes were found after exposures to concentrated ambient air [34], 
diesel exhaust [35-37], or ultrafine particles [38]. In the present tudy, there was no effect of 
filtration on leukocyte count or their subtypes. 
The air filtration was associated with decreased expression of CD62L on monocytes, 
although not consistently throughout the exposure period. This could well be a spurious 
finding because the CD62L expression was positively associated with the decrease in PM2.5 
measured in the living room during the whole exposure period. The unaltered expression of 
adhesion markers CD11b, CD31 and CD49d on monocytes, suggests that pulmonary or 
systemic inflammation was not affected by the exposure contrast achieved in our study. This 
is in keeping with observations that 3-hours inhalation exposure to high concentrations of 
wood smoke particles had no apparent effect on surface marker molecules CD54 (ICAM-1), 
CD11a (ITGAL) and CD62L at 6- or 20-hours after cessation of the exposure [25]. However, 
2-hours inhalation exposure to ultrafine carbon particles in healthy subjects was associated 
with reduced expression of adhesion molecules CD11b/CD18 on monocytes and 
CD11b/CD18 and CD49d on granulocytes [39]. Moreover, chronic biomass smoke exposure 
was associated with increased surface expression of CD11b/CD18 in circulating granulocytes 
and monocytes in Indian women [40]. The association between ambient air pollution 
exposure and expression of CD31 on monocytes has not previously been investigated in 
humans, whereas it has been shown that PM exposure in animals decreased CD31 and 
CD49d expression on circulating monocytes [41]. 
CRP is an important acute phase protein with pro-inflammatory properties associated with 
atherogenesis, modulation of endothelial function and risk of acute myocardial infarction [42] 
and it has been widely used as biomarker in air pollution studies [43]. We found no effect of 
filtration on CRP in keeping with our previous air filtration study in the home [13] and 
controlled short-term exposure studies of welding fumes, diesel exhaust and wood smoke 
[44-47]. In contrast, CRP decreased after filtration of the home air of residents in a wood 
smoke-impacted community [14]. Collectively, our observations from biomarkers of 
systemic inflammation including leukocyte counts, expression of adhesion markers on 
monocytes and CRP indicated minimal low-grade inflammation at baseline, which was not 
further reduced by indoor air filtration. 
We found no effect of air filtration on lung function in the elderly population of the present 
study. Indeed, indoor air filtration appears mainly to alleviate airway symptoms in subjects 
with allergies and asthma [48], although electrostatic air filtration improved lung function in 
young adults from tobacco-polluted homes [15]. 
Plasma levels of CC16 and SPD are used as sensitive biomarkers of epithelial damage in 
lower airways [16,17]. We found no effect of air filtration on CC16 and SPD, suggesting 
intact epithelial barrier function at baseline and thus no effect of air filtration. Similarly, 
CC16 levels were not different after 24-hours exposure to polluted or filtered street air [49]. 
However, elevated CC16 levels have been observed after controlled exposure to wood smoke 
[50,51], whereas subjects using wood fuel for heating had lower levels of CC16 and 
increased SPD levels in a recent cross-sectional study [52]. 
We used a robust study design with 7-repeated measurements in a real-life setting. The 
limitations of this study include our limited statistical power and heterogeneous study 
population aged 51 to 81 years with some taking cardiovascular and/or cycloxygenase 
inhibitor drugs. This might have attenuated potential effects, although stratified analyses 
showed no sign of differential effects comparing active and sham filtration and we had 
reasonable statistical power to detect relevant effects in subjects not taking any drugs. 
However, when accounting for variable filtration efficacy by using the actual decrease 
achieved in PM2.5 in the bedroom we found a positive effect especially among those people 
not taking vasoactive or to some extent other drugs, although there was no statistically 
significant interaction. Nevertheless, this suggests that effects of PM on vascular function 
might be masked by vascular drugs per se or more difficult to de ect because of the existing 
disease they are taken for, similarly to the lack of effect of diesel exhaust exposure on an 
already poor vasomotor function among patients with ischemic heart disease [37]. It should 
also be considered that although this association between the PM2.5 decrease and improved 
MVF is consistent with our previous study, it was found in a post-hoc analysis and was not 
associated with changes in biomarkers that could explain possible mechanisms related to 
inflammation and monocyte activation. Genetically determined susceptibility can also modify 
cardiovascular effect of PM exposures [53,54]. Most importantly, the exposure contrast was 
small because the base-line particle concentration was already latively low, albeit realistic 
exposures in current homes and the participant’s whereabouts were not stricted to the 
monitored rooms. Future studies of efficacy of air filtration could focus on homes with high 
levels of exposure due to outdoor and/or indoor sources and preferably selected by 
measurements in the home before the trial. Moreover, our findings related to the achieved 
decrease in PM2.5 suggest that the bedroom is the most important part of the home for the 
intervention and that effects on MVF can be expected within 48 hours of filtration. 
Unfortunately, personal monitoring of exposure in- and outside the home was not possible in 
our study, although individual time-activity patterns as well as the locations visited determine 
personal exposure to ambient air pollution [55]. Nevertheless, personal exposure to PM2.5 
showed strong correlation with residential concentrations even wheonly 58% of the time 
was spent at home [56]. 
Furthermore, we measured MVF, in the homes of the participants, whereas forearm 
plethysmographic methods applicable in clinical settings might be more sensitive for 
detection of vasomotor dysfunction [28]. Finally, we measured a limited number of 
biomarkers of inflammation, monocyte activation and lung cell integrity at already low levels 
and effects on higher particle-induced levels or on other functions cannot be excluded [2,30]. 
Conclusion 
By comparing active and sham filtration of indoor air in the bedroom and living room for two 
weeks we found no improvement in MVF or lung function or detectable reduction in 
systemic inflammation, monocyte activation or lung cell damage in this elderly population, 
including people taking vasoactive medication, but with relatively low initial exposure levels. 
However, the filtration efficacy was variable and microvascular function was within 2 days 
significantly associated with the actual PM2.5 decrease achieved in the bedroom, particularly 
among subjects not taking any drugs, suggesting that positive effects of filtration require 
substantial exposure contrasts especially in the bedroom and possibly not confounding by 
drug intake or existing disease. 
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